Prosecution Insights
Last updated: April 19, 2026

Agenebio Inc.

4 pending office actions

Portfolio Summary

4
Total Pending OAs
0
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18235753 BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT HERNANDEZ, JACKSON J 1627 Non-Final OA Aug 18, 2023
18015439 COMBINATIONS OF GABAA ALPHA 5 AGONISTS AND SV2A INHIBITORS AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT WHITE, DAWANNA SHAR-DAY 1627 Non-Final OA Jan 10, 2023
18015445 POLYMORPHS OF A GABAA ALPHA5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT BURKETT, DANIEL JOHN 1624 Non-Final OA Jan 10, 2023
17786175 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT CHONG, YONG SOO 1623 Non-Final OA Jun 16, 2022

Managing Agenebio Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month